Margenza
Payments companies reported to CMS as associated with Margenza. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Margenza, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Margenza
These are the largest totals companies reported as associated with Margenza. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mark Pegram | Stanford, CA | Medical Oncology | $3,841.10 |
| Eleni Andreopoulou | Houston, TX | Hematology & Oncology | $2,204.82 |
| Vijayakrishna Gadi | Seattle, WA | Medical Oncology | $1,572.18 |
| Seth Wander | Boston, MA | Hematology & Oncology | $1,500.00 |
| Don Dizon | Providence, RI | Medical Oncology | $1,500.00 |
| Megan Tesch | Boston, MA | Medical Oncology | $1,500.00 |
| Hatem Soliman | Tampa, FL | Hematology & Oncology | $1,369.00 |
| Arun Kumar Arumugam Raajasekar | Yuma, AZ | Hematology & Oncology | $942.00 |
| Sherif Badawy | Chicago, IL | Pediatric Hematology-Oncology | $599.00 |
| Weldon Haw | La Jolla, CA | Ophthalmology | $513.00 |
Prescribed Margenza?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.